CYCN Cyclerion Therapeutics Inc

Price (delayed)

$3.72

Market cap

$126.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.23

Enterprise value

$130.51M

Highlights
Cyclerion Therapeutics's EPS has increased by 42% YoY and by 13% from the previous quarter
The net income rose by 33% year-on-year and by 9% since the previous quarter
The revenue has dropped by 76% year-on-year and by 41% since the previous quarter
The company's gross profit has shrunk by 76% YoY and by 41% QoQ

Key stats

What are the main financial stats of CYCN
Market
Shares outstanding
34.13M
Market cap
$126.98M
Enterprise value
$130.51M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.62
Price to sales (P/S)
94.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.11
Earnings
Revenue
$1.34M
EBIT
-$70.97M
EBITDA
-$69.04M
Free cash flow
-$54.93M
Per share
EPS
-$2.23
Free cash flow per share
-$1.61
Book value per share
$1.42
Revenue per share
$0.04
TBVPS
$2.93
Balance sheet
Total assets
$99.97M
Total liabilities
$51.53M
Debt
$44.96M
Equity
$48.43M
Working capital
$30.98M
Liquidity
Debt to equity
0.93
Current ratio
3.3
Quick ratio
3.08
Net debt/EBITDA
-0.05
Margins
EBITDA margin
-5,137.2%
Gross margin
100%
Net margin
-5,280.7%
Operating margin
-5,354%
Efficiency
Return on assets
-59.8%
Return on equity
-113.8%
Return on invested capital
-74.1%
Return on capital employed
-82%
Return on sales
-5,280.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYCN stock price

How has the Cyclerion Therapeutics stock price performed over time
Intraday
1.09%
1 week
-6.3%
1 month
25.68%
1 year
-17.15%
YTD
21.57%
QTD
33.33%

Financial performance

How have Cyclerion Therapeutics's revenue and profit performed over time
Revenue
$1.34M
Gross profit
$1.34M
Operating income
-$71.96M
Net income
-$70.97M
Gross margin
100%
Net margin
-5,280.7%
Cyclerion Therapeutics's net margin has plunged by 175% YoY and by 56% from the previous quarter
Cyclerion Therapeutics's operating margin has plunged by 173% YoY and by 51% from the previous quarter
The revenue has dropped by 76% year-on-year and by 41% since the previous quarter
The company's gross profit has shrunk by 76% YoY and by 41% QoQ

Growth

What is Cyclerion Therapeutics's growth rate over time

Valuation

What is Cyclerion Therapeutics stock price valuation
P/E
N/A
P/B
2.62
P/S
94.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.11
Cyclerion Therapeutics's EPS has increased by 42% YoY and by 13% from the previous quarter
The equity has contracted by 41% YoY and by 19% from the previous quarter
The stock's price to book (P/B) is 19% more than its last 4 quarters average of 2.2
CYCN's P/S is 88% above its last 4 quarters average of 50.1
The revenue has dropped by 76% year-on-year and by 41% since the previous quarter

Efficiency

How efficient is Cyclerion Therapeutics business performance
Cyclerion Therapeutics's ROS has plunged by 175% YoY and by 56% from the previous quarter
The company's return on equity fell by 18% YoY and by 3.3% QoQ
CYCN's return on assets is down by 9% year-on-year
The return on invested capital has increased by 6% year-on-year and by 3.8% since the previous quarter

Dividends

What is CYCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYCN.

Financial health

How did Cyclerion Therapeutics financials performed over time
Cyclerion Therapeutics's total assets is 94% more than its total liabilities
The quick ratio has contracted by 48% YoY and by 4.3% from the previous quarter
The current ratio has decreased by 46% YoY and by 4.3% from the previous quarter
Cyclerion Therapeutics's debt is 7% less than its equity
Cyclerion Therapeutics's debt to equity has soared by 52% YoY and by 21% from the previous quarter
The equity has contracted by 41% YoY and by 19% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.